Growth and homogenization in China
Regulatory reforms in China, which started in 2015, have contributed to a continued increase in the number of clinical trials of innovative drugs conducted in the country over the following decade. As a result, China contributed 50% of worldwide clinical research activity of this type in 2025, compared with 13% in 2015. But a focus on oncology and specific well-validated drug targets has led to a homogenization of drug discovery. (Nature Reviews Drug Discovery 9 min read)